The company
Regeneron Pharmaceuticals, Inc.
REGN · Nasdaq
Health CareBiotechnologyAbove a falling averageGLP-1
REGN stood above a rising 150-day average in 30 of the last 52 weekly readings, and has been out of that trend for the last 3 weeks. It is 11.5% above that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−14 points in four weeks); Health Care: 28% (−9 points in four weeks).
Statistics
- Rotation
- Above a falling average
- Weeks in an uptrend
- out for 3
- Industry in uptrend
- 18% -14 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $23.9M
- Officials’ trades on record
- 112
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 30 of 52 weeks.
21 Apr – 20 Oct
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
1 Nov 2024 – 1 Oct 2026
Open-market buys above the line and sales below, in dollars. Not yet read: institutions.
Congress and officials
112 disclosed lines: House 89, Senate 12, executive 11; 29 people.
| Who | Did | Amount | Traded |
|---|---|---|---|
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | bought | $50k–$100k | 23 Jul 2026filed 22 Sep 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | bought | $1k–$15k | 17 Jul 2026filed 22 Sep 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | sold | $1k–$15k | 16 Jun 2026filed 22 Aug 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | sold | $100k–$250k | 12 Jun 2026filed 22 Aug 2026 |
| Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31 | sold | $1k–$15k | 15 May 2026filed 8 Jun 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | bought | $100k–$250k | 11 May 2026filed 1 Jul 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | bought | $15k–$50k | 27 Apr 2026filed 1 Jul 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | bought | $1k–$15k | 15 Apr 2026filed 1 Jul 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | bought | $1k–$15k | 7 Apr 2026filed 1 Jul 2026 |
| Alan Armstrong Senate: U.S. Senate eFDSenator | bought | $1k–$15k | 27 Mar 2026filed 21 Jul 2026 |
| Julia Letlow House: U.S. House ClerkLA05 | bought | $1k–$15k | 12 Feb 2026filed 12 Mar 2026 |
| Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31 | bought | $1k–$15k | 18 Nov 2025filed 15 Dec 2025 |
Insiders
Buy orders, 12 months0
Sale orders, 12 months17
Buyers · sellers0 · 8
| Who | Did | Shares | Traded |
|---|---|---|---|
| Andrew J. MurphyCo-Chief Scientific Officer | sold | 6at $753.76 | 14 Oct 2026filed 15 Oct 2026 |
| Andrew J. MurphyCo-Chief Scientific Officer | sold | 35at $755.91 | 14 Oct 2026filed 15 Oct 2026 |
| Andrew J. MurphyCo-Chief Scientific Officer | sold | 16at $757.68 | 14 Oct 2026filed 15 Oct 2026 |
| Andrew J. MurphyCo-Chief Scientific Officer | sold | 24at $758.16 | 14 Oct 2026filed 15 Oct 2026 |
| Andrew J. MurphyCo-Chief Scientific Officer | sold | 14at $759.96 | 14 Oct 2026filed 15 Oct 2026 |
| Andrew J. MurphyCo-Chief Scientific Officer | sold | 74at $760.65 | 14 Oct 2026filed 15 Oct 2026 |
| Andrew J. MurphyCo-Chief Scientific Officer | sold | 27at $761.36 | 14 Oct 2026filed 15 Oct 2026 |
| Andrew J. MurphyCo-Chief Scientific Officer | sold | 55at $762.57 | 14 Oct 2026filed 15 Oct 2026 |
| Andrew J. MurphyCo-Chief Scientific Officer | sold | 25at $763.76 | 14 Oct 2026filed 15 Oct 2026 |
| Andrew J. MurphyCo-Chief Scientific Officer | sold | 219at $764.40 | 14 Oct 2026filed 15 Oct 2026 |
| Andrew J. MurphyCo-Chief Scientific Officer | sold | 271at $765.39 | 14 Oct 2026filed 15 Oct 2026 |
| Andrew J. MurphyCo-Chief Scientific Officer | sold | 279at $766.47 | 14 Oct 2026filed 15 Oct 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Still reading this part; it fills in a moment.
News
Strong Dupixent Trajectory Anchors Regeneron Pharmaceuticals' (REGN) Solid Financial Resultsinsidermonkey.com · 19 Oct 2026Regeneron Pharmaceuticals Inc (REGN) Stock News & Articles247wallst.com · 30 Sep 2026Should You Buy Regeneron Pharmaceuticals Stock Before Oct. 30?aol.com · 28 Sep 2026Investors in Regeneron Pharmaceuticals, Inc. (REGN): Protect Your Rights ...pr-inside.com · 15 Sep 2026Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. (REGN) Investors ...pr-inside.com · 14 Sep 2026Securities Fraud Class Action Filed Against Regeneron Pharmaceuticals, ...pr-inside.com · 13 Sep 2026Lost Money on Regeneron Pharmaceuticals, Inc. (REGN)? Urged to Join ...pr-inside.com · 13 Sep 2026REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud ...gazettextra.com · 10 Sep 2026
Everyone who traded it
Same industry
Government contracts
Awards3
Total$6.8B
Latest12 Jan 2021
PRODUCTION OF THERAPEUTIC IN SUPPORT OF NATIONAL EMERGENCY RESPONSE TO CORONAVIRUS 2019 (COVID-19): IN SUPPORT OF OPERATION WARP SPEED (OWS), THE GOVERNMENT IS PURCHASING UP TO 1,250,000 DOSES OF THE EMERGENCY USE AUTHORIZATION (EUA) THERAPDepartment of Defense · $5.6B · 12 Jan 2021IGF::OT::IGFDepartment of Health and Human Services · $973.6M · 30 Sep 2017IGF::OT::IGF - REGENERON OTHER TRANSACTION AUTHORITY (OTA) AWARDDepartment of Health and Human Services · $278.8M · 21 Sep 2017
From its SEC filings
Analyst forecasts
No analyst forecasts yet.